Search

Your search keyword '"Rebecca Ahn"' showing total 6 results
Start Over Author "Rebecca Ahn"
6 results on '"Rebecca Ahn"'

1. A Synergistic Approach to Outreach and Teaching: Combining Service Learning at the College Level with a Summer Hands-On Outreach Program in Chemical and Biomolecular Engineering for High School Girls

Author

Geeta Verma, Sogol Asaei, Jacob D. Hostert, Rebecca Ahn, and Julie N. Renner

Abstract

A synergetic approach to combine service learning at the university level with a high school outreach program is described. A holistic view is presented by discussing the importance of outreach and service learning, survey results, and outcomes. Overall, it was found that the unique program increased the self-efficacy (belief about one's abilities) of students ranging from high school to graduate level, and positively impacted the social responsibility attitudes of university student participants.

Published
2024
Full Text
View/download PDF

2. Unraveling the Conformations of Backbone and Side Chains in Thermosensitive Bottlebrush Polymers

Author

Rebecca Ahn, Karteek K. Bejagam, Sanket A. Deshmukh, and Samrendra K. Singh

Subjects
chemistry.chemical_classification, Polymers and Plastics, Polymer science, Organic Chemistry, 02 engineering and technology, Polymer, 010402 general chemistry, 021001 nanoscience & nanotechnology, 01 natural sciences, 0104 chemical sciences, Inorganic Chemistry, chemistry, Materials Chemistry, Side chain, 0210 nano-technology
Abstract

This contribution reports the molecular-level conformations of the backbone and side chains of thermosensitive bottlebrush polymers (BBPs) of poly(N-isopropylacrylamide) (PNIPAM) in water. Here, fo...

Published
2019
Full Text
View/download PDF

4. Ophthalmomyiasis Externa due to Oestrus ovis Larvae: A Case Report

Author

Jens Schrecker and Rebecca Ahnert

Subjects
ophthalmomyiasis, larvae, oestrus ovis, Ophthalmology, RE1-994
Abstract

A 23-year-old female presented with redness, itchiness, tearing, and foreign body sensation in her right eye after spending her holiday in Egypt. Slit lamp examination revealed about 15 mobile, whitish maggots that were microbiologically classified as Oestrus ovis larvae. All parasites could be removed without subsequent complications.

Published
2022
Full Text
View/download PDF

5. Pharmaceutical development of IPI-504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer

Author

John Lee, Roger H. Pak, Louis Grenier, Vince Ammoscato, Michael Curtis, Kaiming Li, John Henderson, Matthew Campbell, Denise Mayes, Jason Kropp, Natalie Goltz, Bennett Carter, Johan Sebastian Basuki, Bradley Maurer, Gary Baker, James R. Wright, David Rusch, Rebecca Ahn, Brian C. Austad, Kris Depew, Joseph Helble, Jie Ge, Jason J. Piotrowski, Marlene R. Booth, Julian Adams, Mark Douglas, Steven G. Wong, Laila Kott, James R. Porter, Geoff E. Sylvester, Dumitru Ionescu, Jennifer R. Porter, and Brendan Arsenault

Subjects
Drug, Hydroquinone, Hydrochloride, media_common.quotation_subject, Cancer, Pharmacology, medicine.disease, Hsp90 inhibitor, Quinone, Clinical trial, chemistry.chemical_compound, chemistry, In vivo, Drug Discovery, medicine, media_common
Abstract

IPI-504 (retaspimycin hydrochloride) is an Hsp90 inhibitor that is the subject of multiple clinical trials for the treatment of cancer. IPI-504 is an aqueous soluble (>200 mg/ml) hydroquinone hydrochloride salt of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), a quinone derivative also undergoing clinical evaluation, albeit with suboptimal formulations that address its inferior aqueous solubility (∼50 µg/ml). IPI-504 interconverts with 17-AAG in vivo through oxidation-reduction reactions that result in a dynamic redox equilibrium. The development challenges associated with redox active molecules are significant due to the pH, oxygen, and temperature sensitivities associated with such chemotypes. The API and sterile drug product manufacturing processes thus warrant the monitoring and control of these key variables. Furthermore, the pharmaceutical development challenges associated with cancer agents that are often fast-tracked due to unmet medical needs mandate a rapid development cycle with associated regulatory hurdles. Drug Dev Res 71: 429–438, 2010. © 2010 Wiley-Liss, Inc.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results